The estimated Net Worth of Thomas G Frinzi is at least $2.8 Milion dollars as of 3 January 2023. Mr. Frinzi owns over 87,805 units of Staar Surgical Co stock worth over $2,804,706 and over the last 9 years he sold STAA stock worth over $0. In addition, he makes $0 as Director at Staar Surgical Co.
Sign up
Mr. Frinzi STAA stock SEC Form 4 insiders trading
Thomas has made over 2 trades of the Staar Surgical Co stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 87,805 units of STAA stock worth $2,661,370 on 3 January 2023.
The largest trade he's ever made was exercising 87,805 units of Staar Surgical Co stock on 3 January 2023 worth over $2,661,370. On average, Thomas trades about 8,961 units every 20 days since 2016. As of 3 January 2023 he still owns at least 92,534 units of Staar Surgical Co stock.
You can see the complete history of Mr. Frinzi stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Thomas Frinzi biography
Thomas G. Frinzi serves as Director of the Company. Mr. Frinzi previously served as Worldwide President, Surgical, Johnson & Johnson Vision from February 2017 through December 2019. Mr. Frinzi was Senior Vice President of Abbott Laboratories and President, Abbott Medical Optics (AMO) from January 2016 through February 2017 when Johnson & Johnson acquired AMO. Prior to joining AMO, Mr. Frinzi held a number of leadership positions in ophthalmology and medical device companies. He served as President and CEO of WaveTec Vision from 2010 through 2014. He has also held senior positions in commercial operations, business development, and sales and marketing at Bausch & Lomb Surgical, Refractec and Chiron Vision. Mr. Frinzi earned a bachelor’s degree in political science from the University of Tampa.
How old is Thomas Frinzi?
Thomas Frinzi is 64, he's been the Director of Staar Surgical Co since 2020. There are 4 older and 18 younger executives at Staar Surgical Co. The oldest executive at Staar Surgical Co. is John Moore, 76, who is the Independent Director.
What's Thomas Frinzi's mailing address?
Thomas's mailing address filed with the SEC is 25651, Atlantic Ocean Drive, Lake Forest, Orange County, California, 92630, United States.
Insiders trading at Staar Surgical Co
Over the last 21 years, insiders at Staar Surgical Co have traded over $305,974,767 worth of Staar Surgical Co stock and bought 10,576,326 units worth $122,359,752 . The most active insiders traders include Partners, L.P.Broadwood Cap..., Partners, L.P.Bradsher Neal... oraz Gilbert H Kliman. On average, Staar Surgical Co executives and independent directors trade stock every 26 days with the average trade being worth of $1,643,742. The most recent stock trade was executed by Arthur C Butcher on 12 August 2024, trading 1,315 units of STAA stock currently worth $49,957.
What does Staar Surgical Co do?
staar surgical company (nasdaq: staa), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye has been dedicated solely to ophthalmic surgery for over 30 years. the company offers the evo visian implantable collamer® lenses (icls) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and hyperopic icl, which treats far-sightedness. these lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. all of these lenses are foldable, which permits the surgeon to insert them through a small incision. staar's lens used in refractive surgery is called an implantable collamer lens or "icl". nearly 600,000 visian icls have been implanted to date. it also provides minimally invasive intraocular lenses (iols), including foldable iols for use in minimally invasive cataract surgical procedures; aspheric iols that produce a clearer image than trad
What does Staar Surgical Co's logo look like?
Complete history of Mr. Frinzi stock trades at Staar Surgical Co i Abbott Laboratories
Staar Surgical Co executives and stock owners
Staar Surgical Co executives and other stock owners filed with the SEC include:
-
Caren Mason,
President, Chief Executive Officer, Director -
Scott Barnes,
Chief Medical Officer -
Keith Holliday,
Chief Technology Officer -
Caren L. Mason,
CEO, Pres & Director -
Hans-Martin Blickensdoerfer,
Senior Vice President - Commercial Operations, Direct Markets Europe and China -
Samuel Gesten,
Chief Legal Officer, Corporate Secretary -
Dr. Scott D. Barnes M.D.,
Chief Medical Officer -
James Francese,
Senior Vice President - Commercial Operations, North America and APAC -
Hans-Martin Blickensdoerfer,
Sr. VP of Commercial Operations and Director of Markets - Europe & China -
Dr. Keith Holliday,
Chief Technology Officer -
Patrick F. Williams,
Chief Financial Officer -
Louis Silverman,
Independent Chairman of the Board -
Stephen Farrell,
Independent Director -
John Moore,
Independent Director -
Patrick Williams,
Chief Financial Officer -
Gilbert Kliman,
Director -
Thomas Frinzi,
Director -
Brian Moore,
IR Contact Officer -
Jon Hayashida,
Vice President - Global Clinical and Medical Affairs -
Graydon Hansen,
Chief Manufacturing Officer and Senior Vice President, Global Operations -
Philippe Subrin,
VP of Collamer Lens Manufacturing & GM of Nidau Operations -
Joanne Egamino Ph.D.,
Global Head of Clinical Operations -
James Francese,
Sr. VP of Commercial Operations - North America & APAC -
William Goodmen,
VP of Global HR -
Samuel J. Gesten,
Chief Legal Officer & Corp. Sec. -
Lou Silverman,
Director -
Stephen P Brown,
Vice President & Chief Financi -
Richard A Meier,
Director -
Partners, L.P.Broadwood Cap...,
-
Partners, L.P.Bradsher Neal...,
-
William P Wall,
Director -
David Bailey,
President and CEO -
Robert Studholme,
Senior VP, Operations -
Wei Jiang,
-
Arthur C Butcher,
-
Nathaniel Sisitsky,
General Counsel -
Nicholas T Curtis,
Sr. VP Sales and Marketing -
Paul Hambrick,
Vice President, Operations -
Robert Kenneth Lally,
Vice President, QA/RA -
David L Schlotterbeck,
Director -
James I Farnworth,
VP Reg Affairs & Quality -
Gunther Roepstorff,
President - Domilens GmbH -
John R Gilbert,
Director -
Thomas R Paul,
Vice President - R & D -
John Bily,
Chief Financial Officer -
Volker D Anhaeusser,
Director -
John S Santos,
Sr. VP Planning & Corp Dev -
Jack Steven Roush,
-
Charles P Slacik,
Director -
Robin Hughes,
Vice President, Marketing -
Mark B Logan,
Director -
Barry G Caldwell,
Director -
Don M Bailey,
Director -
Kathryn Tunstall,
Director -
Philippe Subrin,
VP Switzerland OP -
Charles S Kaufman,
V.P. , General Counsel -
Donald J Todd,
President, Asia/Pacific -
Donald L Fagen,
V.P. Sales for N. America -
David R Morrison,
Director -
Craig Felberg,
VP, R&D and Clinical Affairs -
William Walter Goodmen,
Global VP, Human Resources -
Donald Duffy,
Director -
Isamu Kamijo,
President, STAAR Japan Inc. -
K Peony Yu,
Director -
Aimee S Weisner,
-
Magda Michna,
Chief Clinical, Regulatory, -
Warren Foust,
Chief Operating Officer -
Elizabeth Yeu Lin,
-
Lilian Yansheng Zhou,